GeoffreyTGibneyMD

Physician

Overview of Dr. Gibney

Dr. Geoffrey Gibney is an oncologist in Washington, DC and is affiliated with MedStar Georgetown University Hospital. He received his medical degree from University of Connecticut and has been in practice 12 years. Dr. Gibney accepts several types of health insurance, listed below. He is one of 93 doctors at MedStar Georgetown University Hospital who specialize in Oncology. He has more than 80 publications and over 500 citings.

Office
3800 Reservoir Rd NW
Washington, DC 20007
Book by Phone+1(202) 915-9351

Fax+1 202-444-1229
Is this information wrong?

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Boston University Medical CenterResidency, Internal Medicine, 2005 - 2008
Uconn School Of MedicineClass of 2005

Certifications & Licensure

MD State Medical License 2019 - 2024
DC State Medical License 2015 - 2024
FL State Medical License 2011 - 2018
CT State Medical License 2008 - 2016

Clinical Trials

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Start of enrollment: 2010 Aug 13
Completed
Phase 1
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2012 Jul 27
Completed
Phase 1
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Start of enrollment: 2012 Aug 03
Active, not recruiting
Phase 2
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Start of enrollment: 2012 Oct 09
Active, not recruiting
Not Applicable
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor Start of enrollment: 2012 Dec 01
Completed
Phase 1
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) Start of enrollment: 2013 Apr 30
Completed
Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Start of enrollment: 2013 Oct 23
Completed
Phase 2
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER Start of enrollment: 2013 Dec 31
Completed
Phase 1
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Start of enrollment: 2014 Jan 07
Completed
Phase 1
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2014 May 29
Active, not recruiting
Phase 1
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Start of enrollment: 2014 Aug 12
Completed
Phase 2
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma Start of enrollment: 2020 Mar 02
Suspended
Phase 2
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Start of enrollment: 2021 Feb 09
Recruiting
Phase 2
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

7 citations
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber, J., Carlino, M., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M., Kim, K., McKean, M., Long, G., Sullivan, R., Faries, M., Tran, T., Cowey, C., Pecora, A., Sh...> ;Lancet. 2024 Feb 17
1 citations
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.
Gino K In, Jennifer R Ribeiro, Jun Yin, Joanne Xiu, Matias A Bustos, Fumito Ito, Frances Chow, Gabriel Zada, Lindsay Hwang, April K S Salama, Soo J Park, Justin C Mose...> ;NPJ Precision Oncology. 2023 Nov 14
2 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, Diwakar Davar, Geoffrey T Gibney, Omid Hamid, Tina J Hieken, Benjamin Izar, Douglas B Johnson, Rajan P Kulk...> ;Journal for Immunotherapy of Cancer. 2023 Oct 1
117 citations
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost, John R Hyngstrom, Siwen Hu-Lieskovan, Christopher D Lao, Leslie A Fecher, Thach-Giao Truon...> ;The New England Journal of Medicine. 2023 Mar 2
3 citations
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, Zeynep Eroglu, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Tomas Kirchhoff, Carol M Amato, Pau...> ;Journal for Immunotherapy of Cancer. 2022 Nov 1
15 citations
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Sco...> ;Clinical Cancer Research. 2022 Sep 1
4 citations
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.
Gino Kim In, Aparna Nallagangula, Jacob Seung Choi, Lisa Tachiki, Matthew J Blackburn, Stephen Capone, Kathryn B Bollin, Daniel Y Reuben, Keisuke Shirai, Sandy Zhang-N...> ;Journal for Immunotherapy of Cancer. 2022 May 1
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions.
Sourat Darabi, Andrew Elliott, David R Braxton, Jia Zeng, Kurt Hodges, Kelsey Poorman, Jeff Swensen, Basavaraja U Shanthappa, James P Hinton, Geoffrey T Gibney, Justin...> ;Cancers. 2022 Mar 15
8 citations
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.
Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, Neil J. Shah, David M Swoboda, Kellie Gardner, Arash Radfar, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refa...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
38 citations
The State of Melanoma: Emergent Challenges and Opportunities.
Michael B. Atkins, Clara Curiel-Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre-Ghiso, Maria S. Soengas, Ashani T. Weeraratna, Keith T. ...> ;Clinical Cancer Research. 2021 Jan 7
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy.
Aidan M Burke, Michael Carrasquilla, Walter C Jean, Brian T Collins, Amjad N Anaizi, Michael B Atkins, Geoffrey T Gibney, Sean P Collins> ;Frontiers in Oncology. 2021 Jan 1
19 citations
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Georgina V. Long, Caroline Robert, Marcus O. Butler, Félix Couture, Matteo S. Carlino, Steven J. O'Day, Victoria Atkinson, Jonathan Cebon, Michael P. Brown, Stéphane D...> ;Clinical Cancer Research. 2021 Jul 1
36 citations
Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.
Jeff Owsley, Matthew K Stein, Jason Porter, Gino K. In, Mohamed E. Salem, Steven J. O'Day, Andrew Elliott, Kelsey Poorman, Geoffrey T. Gibney, Ari M. Vanderwalde> ;Experimental Biology and Medicine. 2021 Jan 1
2 citations
A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis.
J. Randall Patrinely, Elisa Funck-Brentano, Khang Nguyen, Suthee Rapisuwon, Joe-Elie Salem, Geoffrey T. Gibney, Matteo S. Carlino, Douglas B. Johnson> ;The Oncologist. 2021 Mar 1
17 citations
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases.
Gino K. In, Kelsey Poorman, Michelle Saul, Steven J. O'Day, Jeffrey M. Farma, Anthony J. Olszanski, Michael S. Gordon, Jacob Stephen Thomas, Burton L. Eisenberg, Lawre...> ;Oncotarget. 2020 Aug 18
79 citations
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Neil J. Shah, Ghassan Al-Shbool, Matthew Blackburn, Michael R. Cook, Anas Belouali, Stephen V. Liu, Subha Madhavan, Aiwu Ruth He, Michael B. Atkins, Geoffrey T. Gibney...> ;Journal for Immunotherapy of Cancer. 2019 Dec 17
162 citations
The current state of molecular testing in the treatment of patients with solid tumors, 2019
Wafik S. El-Deiry, Richard M. Goldberg, Heinz-Josef Lenz, Anthony F. Shields, Geoffrey T. Gibney, Antoinette R. Tan, Jubilee Brown, Burton L. Eisenberg, Elisabeth I. H...> ;CA. 2019 Jul 1
5 citations
Linear IgA Disease of the Gingiva Following Nivolumab Therapy.
Sushma Jonna, Mirdza E. Neiders, Suresh Lakshmanan, Amir Khan, Timothy DeKlotz, Dominic Lanasa, Geoffrey T. Gibney, Stephen V. Liu> ;Journal of Immunotherapy. 2019 Nov 1
6 citations
Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.
Lise Boussemart, Adrienne Johnson, Alexa B. Schrock, Sumanta K. Pal, Garrett M. Frampton, David Fabrizio, Zachary R. Chalmers, Michal Lotem, Geoffrey T. Gibney, Jeffer...> ;Journal of the American Academy of Dermatology. 2019 Jun 1
68 citations
YAP/TAZ inhibition induces metabolic and signaling rewiring resulting in targetable vulnerabilities in NF2-deficient tumor cells
Shannon M. White, Maria Laura Avantaggiati, Ivan Nemazanyy, Cristina Di Poto, Yang Yang, Mario Pende, Geoffrey T. Gibney, Habtom W. Ressom, Jeffery Field, Michael B. A...> ;Developmental Cell. 2019 May 6
55 citations
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert C. New...> ;Journal for Immunotherapy of Cancer. 2019 Mar 20
9 citations
Choice of first‐line therapy in metastatic melanoma
Geoffrey T. Gibney, Michael B. Atkins> ;Cancer. 2019 Mar 1
36 citations
Clinical characterization of colitis arising from anti-PD-1 based therapy
Daniel Y. Wang, Meghan J. Mooradian, Dae Won Kim, Neil J. Shah, Sarah E. Fenton, Robert M. Conry, Rutika Mehta, Ann W. Silk, Alice Zhou, Margaret L. Compton, Rami N. A...> ;Oncoimmunology. 2019 Jan 2
42 citations
Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma
Zeynep Eroglu, Y. Ann Chen, Geoffrey T. Gibney, Jeffrey S. Weber, Ragini R. Kudchadkar, Nikhil I. Khushalani, Joseph Markowitz, Andrew S. Brohl, Leticia Tetteh, Howida...> ;Clinical Cancer Research. 2018 Nov 15
47 citations
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
Kendall F. Moseley, Jarushka Naidoo, Clifton O. Bingham, Michael A. Carducci, Patrick M. Forde, Geoffrey T. Gibney, Evan J. Lipson, Ami A. Shah, William H. Sharfman, L...> ;Journal for Immunotherapy of Cancer. 2018 Oct 11
Join now to see all

Press Mentions

Key Studies Conducted at Georgetown Lombardi Lead to Better Treatment for People with MelanomaMarch 1st, 2023
Advancement in Melanoma Treatment Found to Significantly Improve Survival Rates in PatientsSeptember 30th, 2022
Rethinking Immunotherapy for Cancer: When Is the Best Time to Stop?December 28th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

MedStar Georgetown University HospitalWashington, District of Columbia

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment